XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
CALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive ki
(Financial Post, 2025-10-20T22:48:35Z)